Comparative Pharmacology
Head-to-head clinical analysis: BUTISOL SODIUM versus SODIUM PENTOBARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTISOL SODIUM versus SODIUM PENTOBARBITAL.
BUTISOL SODIUM vs SODIUM PENTOBARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing inhibitory neurotransmission. At high doses, it acts as a GABA mimetic and depresses neuronal excitability.
Oral: 50-100 mg 3-4 times daily; maximum 600 mg daily.
IV: 100-150 mg administered over 1-2 minutes for induction of anesthesia; for seizure control, 100 mg IV every 5-10 minutes up to 500 mg. For maintenance of anesthesia, 50 mg IV as needed every 15-30 minutes. IM: 150-200 mg for preoperative sedation.
None Documented
None Documented
Terminal elimination half-life: 40-70 hours (mean 60 h) in adults; prolonged in elderly, hepatic impairment, and neonates (up to 100 h). Clinical context: Accumulation occurs with repeated dosing.
15-50 hours (dose-dependent; prolonged in hepatic impairment).
Primarily hepatic metabolism (80%) with renal excretion of inactive metabolites (<30% unchanged). Less than 1% excreted in feces.
Renal (25-50% unchanged); hepatic metabolism to inactive metabolites; fecal <5%.
Category C
Category D/X
Barbiturate
Barbiturate